CYRX

CryoPortC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+1

B+

Bull case

30%

Probability

Target price

$14.00

-11.1% vs current

Most likely

Base case

45%

Probability

Target price

$12.00

-23.8% vs current

B-

Bear case

25%

Probability

Target price

$8.50

-46.0% vs current

AI sentiment snapshot

Latest data as of 2026-05-04

AI commentary

Primary-source tone turned more constructive on May 4, 2026 because Cryoport paired a revenue beat-versus-prior internal trajectory with a guidance raise and better adjusted EBITDA. However, this remains a tentative monitoring-style earnings update rather than a standard-conviction report: regular-session price data available at 20:05 UTC on May 4 showed CYRX at $10.19 versus the $10.35 May 1 anchor, which does not provide a clean post-release reaction signal, no reliable post-print analyst revision set was confirmed from the checked sources, and the packet-listed peers are mostly contextual rather than direct operating comparators. Headline buzz is medium because the earnings release is clearly material, but coverage remains thin.

RankAlpha Sentiment Codex - 2026-05-04

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-04catalystQ1 2026 revenue growth, EBITDA improvement, and raised FY26 guide reset the near-term earnings setupHigh impact

Cryoport reported Q1 2026 revenue of $47.8 million, up 16% year over year, commercial CGT revenue up 26% to $9.1 million, adjusted EBITDA from continuing operations improving to negative $0.6 million from negative $2.8 million, and raised full-year 2026 revenue guidance to $192 million-$196 million from the prior $190 million-$194 million range. That is the clearest incremental positive change versus the prior monitoring thesis, but it is still a T+1 update with limited external revision data. [#PR-2026-05-04]

2026-12-31eventCustomer approval cadence and clinical-program conversion remain the main external demand leverHigh impact

Cryoport said it supported 766 global clinical trials and 21 commercially approved CGTs as of March 31, 2026, after previously guiding to multiple 2026 BLA/MAA filings and approvals. Because Cryoport sells infrastructure and services into the CGT ecosystem, customer regulatory wins and late-stage program conversions remain a real revenue driver even though they are not company-owned drug catalysts. [#PR-2026-05-04] [#8-K-2026-03-03]

2026-12-31catalystCash runway and 2026 facility launches are the distinct long-horizon financing and execution testHigh impact

Management highlighted planned BioServices operations at the Paris Global Supply Chain Center in Q3 2026 and the planned opening of the Santa Ana Global Supply Chain Center in Q4 2026, while ending Q1 with $403.6 million of cash, cash equivalents, and short-term investments. For this non-therapeutic CGT infrastructure business, the long-horizon catalyst is not a drug readout; it is whether Cryoport can use its cash runway to fund the 2026 footprint expansion and convert those facilities into utilization, revenue growth, and margin progress without renewed financing pressure. [#PR-2026-05-04] [#10-K-2026-03-05]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-04 • Updated nightlySource: Internal modelMethodology